Elicit: B-cell Biomarkers and Ocrelizumab Response

B-cell Biomarkers and Ocrelizumab Response

Which biomarkers of B-cell depletion correlate with clinical response to ocrelizumab?

CD19+ B-cell counts, plasmablast levels, baseline regulatory cell populations (CD49d+ T-cells and B-1a cells), and CD8+ T-cell depletion correlate with clinical response to ocrelizumab, with the relative importance of each biomarker varying by MS subtype and baseline inflammatory status.

Abstract

Multiple biomarkers of B-cell depletion correlate with clinical response to ocrelizumab, though their predictive value varies by clinical context. Total CD19+ B-cell depletion showed consistent associations with outcomes in RRMS, with higher ocrelizumab exposure producing lower B-cell counts and reduced disability progression (HR 0.64, p=0.0135). Baseline CD19+ counts predicted repopulation kinetics, with counts ≥12-14% identifying patients at risk for fast repopulation and higher MRI activity (17.39% vs. 2.53%, p=0.008). Plasmablast levels emerged as particularly informative: responders at 24 months had 3-fold lower plasmablasts at 6 months compared to non-responders (7.69% vs. 22.66%, p=0.043), and plasmablast populations correlated positively with 12-month EDSS scores (R=0.564, p=0.004). However, in PPMS, baseline inflammatory status determined which biomarkers mattered—B-cell repopulation and serum neurofilament levels predicted outcomes in Gd+ patients, while serum IgA levels and T-cell remodeling were more relevant in Gd- patients. Elevated baseline regulatory populations (CD49d+ T-cells, B-1a cells) predicted achievement of NEDA-3 status, while CD8+ T-cell modulation correlated with disability outcomes (OR=1.01, p=0.02). Treatment-naive patients demonstrated stronger biomarker-outcome correlations than previously treated patients (HR=2.53 for radiological activity with prior treatment, p=0.039), suggesting prior therapies modify B-cell compartment dynamics and diminish predictive accuracy of standard depletion metrics.

Methods

We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 5 key aspects that mattered most to the research question.

Records from Elicit search

Data extraction

B-Cell Depletion Biomarkers

Clinical Response Measures

Biomarker-Response Correlations

Patient Characteristics

Key Findings

Synthesis

The studies reveal complex, context-dependent relationships between B-cell depletion biomarkers and clinical response to ocrelizumab. Rather than a single biomarker universally predicting outcomes, different markers appear relevant in different clinical contexts.

MS Subtype as a Context Modifier

The relevance of specific biomarkers varies by MS subtype. In RRMS populations, total B-cell depletion metrics (CD19+ counts, repopulation kinetics) showed strong associations with clinical outcomes.

The Plasmablast Paradox

Multiple studies identified plasmablasts as paradoxically important despite representing a small fraction of circulating B cells. This suggests residual plasmablasts may sustain pathogenic antibody production or represent reservoirs for rapid B-cell reconstitution.

Baseline Biomarkers Versus Dynamic Markers

Studies diverged on whether baseline or post-treatment biomarker levels better predicted outcomes, likely reflecting different mechanistic questions.

The T-Cell Connection: Indirect Effects of B-Cell Depletion

Several studies identified T-cell populations as biomarkers despite ocrelizumab targeting CD20.

Treatment History as a Confounding Factor

Previous treatment exposure consistently modified biomarker-response relationships. This suggests that prior treatments alter the B-cell compartment’s composition and repopulation capacity.

Dose-Response and Threshold Effects

The exposure-response analysis revealed a critical asymmetry: different disease processes have different B-cell dependency thresholds.

Reconciling Heterogeneity: Toward an Integrated Model

The apparent heterogeneity in biomarker findings reflects that B-cell depletion operates through multiple mechanisms that vary by clinical context.

References

  1. Ece Akbayır et al. (2025). B‐Cell and T‐Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple Sclerosis.
  2. M. Boziki et al. (2022). Ocrelizumab in Patients with Active Primary Progressive Multiple Sclerosis: Clinical Outcomes and Immune Markers of Treatment Response.
  3. J. I. Fernández-Velasco et al. (2021). Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS.
  4. Alice Willison et al. (2025). Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis.
  5. M. Cellerino et al. (2021). Predictors of Ocrelizumab Effectiveness in Patients with Multiple Sclerosis.
  6. Hany Mohammed Amin Aref et al. (2024). Follow Up of Total B Cells (CD 19) Count after B Cell Depleting Therapy in Relapse Remitting Multiple Sclerosis Disorder in Egyptian Patients.
  7. G. Abbadessa et al. (2021). CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with Ocrelizumab.
  8. J. I. Fernández-Velasco et al. (2022). Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology.
  9. Nicola Capasso et al. (2022). Ocrelizumab effect on humoral and cellular immunity in multiple sclerosis and its clinical correlates: a 3-year observational study.
  10. S. Hauser et al. (2023). Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.